Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods to treat Gorlin Syndrome in a subject and preventing basal cell carcinomas in a Gorlin Syndrome subject. In some embodiments, the method comprises administering to the subject an anhydrous rapamycin gel composition disclosed herein. In some embodiments, administration comprises applying the composition as a thin layer on the subject's skin. In some embodiments, the composition is administered once daily.

Abstract: In one aspect, compounds are provided that can inhibit salt-inducible kinases (SIK) and methods of treating a disease or disorder using the compounds.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of EGFR inhibitors. In one embodiment, a topical anhydrous composition includes one or more EGFR inhibitors, one or more solvents, one or more gelling agents, and, optionally, one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: The invention provides a composition comprising benzoyl peroxide or derivative thereof; and at least one antibiotic compound selected from pseudomonic acid, retapamulin, fusidic acid and derivatives thereof; methods and uses of a composition of the invention in the treatment of at least one topical disease or disorder and kits comprising a composition of the invention.

Abstract: A topical composition and method for treating seborrehic dermatitis designed specifically to allow for short duration skin contact time. It is a water rinseable sulfacetamide composition free of elemental sulfur, preferably dosed in a regimen of at least two daily treatments.

Abstract: A powder composition which reacts in water to form in situ peroxycarboxylic acids at an anti-microbially effective concentration. Importantly, its utility is both for topical anti-microbial application and for effective low temperature disinfection/sterilization of instruments. It comprises the combination of a perborate, one or more novel acyl and/or aroyl donors, a buffering system which allows the pH to arise to about 9 for rapid formation of the peroxycarboxylic acids and then drop to about 7.5 for sustained stability and microbial kill. It preferably includes a surfactant facilitating antimicrobial efficacy, as well as other minors.

Abstract: An enzymatic wound debrider which employs in combination a topical dosage form pharmaceutical carrier and a debridement agent which is thermolysin preferably in combination with an ionic co-factor of either zinc ions, or calcium ions, or both.

Abstract: An enzymatic wound debrider which employs in combination a topical dosage form pharmaceutical carrier and a debridement agent which is thermolysin preferably in combination with an ionic co-factor of either zinc ions, or calcium ions, or both.